General
Preferred name
VERAPAMIL
Synonyms
VERAPAMIL HYDROCHLORIDE ()
(±)-Verapamil hydrochloride ()
Dexverapamil ()
(¡À)-Verapamil hydrochlorid ()
(??)-Verapamil hydrochlorid ()
Verapamil HCl ()
Manidon ()
Calcan hydrochloride ()
Verapamyl hydrochloride ()
Verapamil (hydrochloride) ()
(±)-Verapamil hydrochloride ()
Benzeneacetonitrile, Alpha-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-Alpha-(1-methylethyl)-, (R)- ()
(±)-Verapamil ()
CP-16533-1 ()
(±)-Verapamil (hydrochloride) ()
CP-16533-1 (hydrochloride) ()
Verapamil (CP-16533-1) HCl ()
(¡À)-Verapamil hydrochloride ()
Cordilox MR 240 ()
Vertab SR 240 ()
Calan ()
Ranvera MR ()
Securon Mid ()
Half Securon SR ()
Zolvera ()
Covera ()
NSC-657799 ()
Covera-HS ()
Securon ()
Verapress MR 240 ()
LU-20175 ()
Securon IV ()
Manidon SR ()
Berkatens ()
Verapamili hydrochloridum ()
Geangin ()
Univer ()
Cordilox ()
Ethimil MR 240 ()
Verelan ()
Securon SR ()
Cordilox I.V. ()
Verelan pm ()
Isoptin Sr ()
Isoptin ()
Vera-Til SR ()
Calan Sr ()
NSC-272366 ()
NSC-272306NA ()
CP-16,533-1 ()
D-365 ()
Tarka ()
Verapamil slow release ()
CP-165331 ()
Iproveratril ()
Verapamil (hydrochloride) ()
(±)-Verapamil-d3 (hydrochloride) ()
P&D ID
PD009864
CAS
152-11-4
52-53-9
56949-77-0
38176-10-2
2714485-49-9
Tags
natural product
drug
available
Approved by
FDA
First approval
1981
Drug Status
approved
Drug indication
Cardiac Depressant (anti-arrhythmic)
Cardiac Depressant (anti-arrhythmic),Vasodilator (coronary)
Anti-Anginal
Coronavirus Disease 2019 (COVID-19)
Hypertension
Max Phase
Phase 4
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION The approved drug verapamil is a racemic mixture of two enantiomers (PubChem CID 92305 and PubChem CID 65808). The structure shown here does not specify stereochemistry and represents the mixture. Marketed formulations may contain verapamil hydrochloride (PubChem CID 62969). (GtoPdb)
DESCRIPTION L-type Ca2+ channel modulator; adrenoceptor antagonist; antiarryhthmic; cardiac depressant; coronary vasodilator (LOPAC library)
DESCRIPTION P2X antagonist (Tocris Bioactive Compound Library)
Cell lines
26
Organisms
9
Compound Sets
34
Axon Medchem Screening Library
3452
Cayman Chemical Bioactives
14288
18452
ChEMBL Approved Drugs
CHEMBL1280
CHEMBL6966
ChEMBL Drugs
CHEMBL1280
CHEMBL6966
Concise Guide to Pharmacology 2017/18
2406
Concise Guide to Pharmacology 2019/20
2406
Concise Guide to Pharmacology 2021/22
2406
Concise Guide to Pharmacology 2023/24
2406
Drug Repurposing Hub
DrugBank
DB00661
DrugBank Approved Drugs
DB00661
DrugCentral
2815
DrugCentral Approved Drugs
2815
DrugMAP
DM0ASTP
DMA7PEW
DrugMAP Approved Drugs
DMA7PEW
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101717
Guide to Pharmacology
2406
Ki Database
VERAPAMIL
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL6966
MedChem Express Bioactive Compound Library
HY-A0064
HY-14275
NCATS Inxight Approved Drugs
CJ0O37KU29
NIH Clinical Collections (NCC)
NIH Mechanistic Set
Novartis Chemogenetic Library (NIBR MoA Box)
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
verapami-hcl
TargetMol Bioactive Compound Library
T1010
The Spectrum Collection
Tocris Bioactive Compound Library
0654
VGSC-DB
NA0014
External IDs
79
Properties
(calculated by RDKit )
Molecular Weight
454.28
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
13
Ring Count
2
Aromatic Ring Count
2
cLogP
5.09
TPSA
63.95
Fraction CSP3
0.52
Chiral centers
1.0
Largest ring
6.0
QED
0.42
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Selectivity
L-type
Pathway
Membrane Transporter/Ion Channel
Metabolic Enzyme/Protease
Neuronal Signaling
Target
Calcium Channel
CACNA1A, CACNA1B, CACNA1C, CACNA1D, CACNA1F, CACNA1G, CACNA1I, CACNA1S, CACNB1, CACNB2, CACNB3, CACNB4, CYP3A4, KCNA10, KCNA7, KCNH2, KCNJ11, NALCN, SCN5A, SLC29A4, SLC6A4
Ca channel antagonist
Cytochrome P450
P-glycoprotein
Calcium Channel,P450 (e.g. CYP17),P-gp
Primary Target
CaV1.x Channels (L-type)
MOA
Blocker
Dopamine D2 Antagonists
L-Type Calcium Channel Blockers
Calcium Channel Blockers
calcium channel blocker
Member status
member
Indication
hypertension
Therapeutic Class
Analgesics
Antiviral Agents
VGSC Target
Nav1.5
Source data